Effect of substitutive growth hormone therapy on myopia control among Chinese children
Asia-Pacific Journal of Ophthalmology · 2025
DOI: 10.1016/j.apjo.2025.100137 ↗Kurz gefasst
Fachartikel in der Zeitschrift Asia-Pacific Journal of Ophthalmology, 2025. Verfasst von Yi Lu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; National Clinical Research…. Hauptthemen laut MEDLINE: Human Growth Hormone, Refraction, Ocular, Myopia. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
PURPOSE: To explore the correlation between recombinant human growth hormone (rhGH) therapy and myopia progression, and to optimize the myopia control strategies in myopic children undergoing rhGH therapy. METHODS: This retrospective study included 27 myopic children receiving rhGH therapy and 57 myopic children in the control group, all of whom underwent myopia interventions. Axial length (AL) and refraction were measured by IOLMaster and an autorefractor after cycloplegia. AL changes were compared between the rhGH and control groups, before and after rhGH therapy, and among different myopia control strategies. Univariate and multivariate regression models analyzed factors associated with axial elongation. RESULTS: The rhGH group exhibited greater median AL change than the control group (0.29 mm/year; interquartile range [IQR], 0.19-0.40; n = 27 vs. 0.18 mm/year; IQR, 0.12-0.27; n = 57; P < 0.001). Median axial elongation increased after rhGH treatment (0.22 mm/year; IQR, 0.12-0.34 vs. 0.32 mm/year; IQR, 0.26-0.40; n = 14; P = 0.026), while it decreased after cessation (0.39 mm/year; IQR, 0.16-0.56 vs. 0.04 mm/year; IQR, -0.03-0.15; n = 6; P = 0.031). After adjusting for confounders, axial elongation was faster in the rhGH group (β = 0.13, P < 0.001). Longer rhGH therapy duration and shorter myopia control duration were associated with accelerated axial elongation (β = 0.13, P = 0.027). Dual-therapy myopia control appeared to mitigate excessive axial elongation in rhGH-treated children more effectively than monotherapy (0.27 mm/year; IQR, 0.18-0.31; n = 20 vs. 0.40 mm/year; IQR, 0.32-0.70; n = 7; P = 0.026). CONCLUSIONS: Myopic children undergoing rhGH therapy would exhibit accelerated axial elongation despite myopia control. Close monitoring and dual-therapy myopia control strategies are recommended for these children.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; National Clinical Research Center for Eye Diseases, Shanghai, China; Shanghai Key Laboratory of…
- Shanghai Engineering Center for Precise Diagnosis and Treatment of Eye Diseases, Shanghai, China.
- Hangzhou Chaoju Eye Hospital, Hangzhou, Zhejiang Province, China.
- Hangzhou Chaoju Eye Hospital, Hangzhou, Zhejiang Province, China. Electronic address: jinji2@sina.com.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Lu, Y., Xie, J., Cheng, L., Fu, Q., Wu, M., Jin, J., & Xu, X. (2025). Effect of substitutive growth hormone therapy on myopia control among Chinese children. Asia-Pacific Journal of Ophthalmology. https://doi.org/10.1016/j.apjo.2025.100137
Vancouver
Lu Y, Xie J, Cheng L, Fu Q, Wu M, Jin J, et al. Effect of substitutive growth hormone therapy on myopia control among Chinese children. Asia-Pacific Journal of Ophthalmology. 2025. doi:10.1016/j.apjo.2025.100137
BibTeX
@article{Lu2025,
author = {Lu, Yi and Xie, Jiamin and Cheng, Lele and Fu, Qingdong and Wu, Miao and Jin, Ji and Xu, Xun},
title = {Effect of substitutive growth hormone therapy on myopia control among Chinese children},
journal = {Asia-Pacific Journal of Ophthalmology},
year = {2025},
doi = {10.1016/j.apjo.2025.100137}
}
EUVIMED